Review Article • บทฟื้นฟูวิชาการ

Paracetamol for Peri-operative Anesthesia Care

Kanittha Chongwilaiwan, Pattharaporn Sombood, Tuanlutfee Tuwanhayee, Phongthara Vichitvejpaisal
Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Abstract

This review encapsulates paracetamol's pharmacokinetics, pharmacodynamics, and pharmacogenomics. Preclinical and experimental evidence underscores paracetamol's unique analgesic effects, examining animal models, dose-response relationships, and its influence on inflammatory and nociceptive pathways. In the clinical realm, paracetamol emerges as a cornerstone of multimodal analgesia, targeting peri-operative pain challenges. This article explores paracetamol's role in diverse surgical contexts, and in special patient populations. Notably, paracetamol's ability to reduce opioid consumption while preserving effective pain control is examined, alongside its impact on post-operative outcomes and patient satisfaction.

Keywords: acetaminophen, multimodal analgesia, pain management, paracetamol, peri-operative anesthesia care

Peri-operative anesthesia care plays a pivotal role in modern surgical medicine, serving the dual purpose of ensuring pain-free procedures and optimizing post-operative recovery. Within this realm, adjunctive analgesics, notably acetaminophen or paracetamol, have garnered substantial attention for their potential to enhance pain management, reduce reliance on opioids, and mitigate the adverse effects associated with traditional analgesic medications. These agents are seamlessly integrated into multimodal analgesic strategies that aim to enhance the overall peri-operative experience, alleviate discomfort, and expedite the recovery.[1,2] This exploration encompasses an examination of its pharmacokinetics, pharmacodynamics, and pharmacogenomics. It offers a comprehensive overview within various surgical contexts, detailing paracetamol's influence on pain management, its role in multimodal analgesia, potential complications, and its impact on patient outcomes.

Pharmacokinetics

Absorption: Following oral administration, paracetamol undergoes rapid and near-complete absorption from the gastrointestinal tract. Intravenous (IV) and rectal formulations of paracetamol are available. Paracetamol typically exhibits a relatively rapid onset of action, usually within 30 min to 1 h after oral ingestion. For IV administration, its effects

Correspondence to: Phongthara Vichitvejpaisal, E-mail: phongthara@gmail.com
Received April 11, 2024, Revised June 9, 2025, Accepted June 9, 2025

become evident in approximately 5 to 10 min, while the rectal route typically takes effect within 15 to 30 min. The rate of absorption diminishes when paracetamol is ingested with food in the stomach or concurrently with opioid or anticholinergic drugs that extend gastric emptying time. Conversely, the absorption rate increases when administered with metoclopramide.[3]

Distribution: Paracetamol demonstrates a moderate volume of distribution (Vd) and distributes extensively throughout the body, displaying a distinct affinity for the liver. Although it easily traverses the blood-brain barrier, it exhibits minimal binding to plasma proteins. The low Vd post-absorption is predominantly within the blood and does not significantly cross the placenta. Only negligible amounts enter breast milk. In adults, the distribution volume is 1 L/kg, and in children, it ranges from 0.7 to 1.2 L/kg, with binding occurring to a lesser extent-approximately 10-25% of blood proteins. *Metabolism:* The majority of paracetamol undergoes metabolism in the liver (the first pass effect). The primary metabolic pathway involves conjugation with glucuronic acid and sulfate, leading to the formation of water-soluble metabolites that are eventually excreted in the urine. However, a smaller portion of paracetamol is metabolized by the cytochrome P450 enzyme system in the liver, potentially leading to the formation of a highly reactive and toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI). This metabolite is typically detoxified by the availability of glutathione in the liver. However, in cases of paracetamol overdose, when glutathione is depleted, NAPQI can cause severe hepatotoxicity.

Elimination: The primary route of excretion for paracetamol and its metabolites is through the urine. The half-life of paracetamol typically spans from 2 to 3 h in adults, though this duration may fluctuate based on variables such as age, liver function, and dosage. Renal clearance for paracetamol is estimated to be between 0.16 and 0.2 ml/min/kg, with less than 5% excreted in its unchanged form and approximately 2.6% undergoing biliary excretion.[4]

Pharmacodynamics

Paracetamol inhibits the enzyme cyclooxygenase (COX), primarily in the central nervous system, with limited anti-inflammatory properties compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs). It selectively reduces COX activity, especially COX-2, responsible for prostaglandin synthesis, thereby reducing inflammation, pain, and fever through decreased prostaglandin production.[3] Paracetamol shares analgesic and antipyretic effects with NSAIDs but stands out for its more pronounced impact on analgesia and antipyresis, with weaker anti-inflammatory activity. Its antipyretic action involves inhibiting the hypothalamic heat-regulating center. The mechanism of its analgesic effect, while not fully understood, may include inhibiting central prostaglandin synthesis and raising the pain threshold. Paracetamol induces analgesia by inhibiting the COX isoenzyme, particularly COX-2, acting as a reducing co-substrate at the peroxidase site.

Proposed mechanisms for analgesia involve indirect activation of cannabinoid

receptors, modulation of serotoninergic and opioid pathways, inhibition of nitric oxide production, and attenuation of hyperalgesia induced by substance.[5] Paracetamol's impact on pain pathways is intricate, influencing pain perception by modulating central and peripheral nociceptive signaling. Its primary action occurs in the central nervous system, reducing pain perception without significantly affecting inflammation. This makes it valuable in peri-operative analgesia, offering pain relief without impeding the body's natural response to surgical trauma.

Pain receptors, or nociceptors, are distributed throughout the body, responding to cellular injury. Activated nociceptors release chemical mediators, transmitting nerve impulses from the peripheral to the central nervous system. This intricate process, known as the "ascending pathway", involves various regions like the dorsal horn, spinothalamic tract, medulla, midbrain, and thalamus, where pain is recognized and relayed to the cortex. The signal then travels back through the descending pain-inhibitory pathway from the periaqueductal grey region in the midbrain and medulla oblongata to dorsal horn cells. Paracetamol engages with various mechanisms in these pain pathways.

Paracetamol stimulates a central serotonergic mechanism in the descending inhibitory pain pathways, contributing to pain relief.[6] By inhibiting prostaglandin H2 synthase (COX), paracetamol hinders the conversion of arachidonic acid to prostaglandin, playing a crucial role in mitigating pain and fever. N-arachidonoylaminophenol, AM404 is an active metabolite generated in the body during the metabolism of paracetamol. The indirect activation of the cannabinoid receptor AM404 results in the inhibition of endogenous cannabinoid reuptake, ultimately leading to the alleviation of pain and a reduction in body temperature.[5,7] Moreover, paracetamol interferes with the nitric oxide pathway, a neuro-transmitter involved in transmitting painful nerve impulses within the spinal cord.

Pharmacogenomics

Pharmacogenomics involves customizing paracetamol dosages based on an individual's genetic makeup, optimizing pain management, mitigating the risk of under- or over-dosing, and improving the overall patient experience. Genetic factors significantly influence the efficiency, efficacy, and effectiveness of paracetamol, particularly in its metabolism, primarily governed by the cytochrome P450 enzyme system.[8] Genetic variations in CYP2E1 can impact the rate of paracetamol metabolism. Fast metabolizers swiftly convert paracetamol into its metabolites, while slow metabolizers experience slower clearance, potentially elevating the risk of toxicity.[8,9] Genes encoding UDP-glucuronosyltransferases (UGTs), involved in paracetamol conjugation, influence drug metabolism, resulting in varied responses among individuals.[10] Genetic variations in glutathione S-transferase (GST) genes affect the detoxification of NAPQI, the toxic metabolite of paracetamol. Key enzymes in toxic NAPQI production include CYP2E1 and CYP2D6, making them crucial in pharmacogenetic screening. UGT1A6*2, may contribute to

potential paracetamol toxicity.

Genetic factors, such as SULT1A1*2, in certain populations may impact enzyme activity, potentially leading to interindividual paracetamol toxicity. High frequencies of GSTM10, GSTT10, and GSTP1*B, associated with absent enzyme expression and decreased activity, warrant screening in specific populations. Furthermore, the enzyme FAAH and its variant P129T may play a role in the analgesic effects of paracetamol, making FAAH detection important in understanding therapeutic pharmacology. Deacetylation by N-deacetylase enzymes and potential pathways involving NAPQI as a substrate require further study to understand paracetamol nephrotoxicity. The genotypes of UGT, SULT, CYP450, GST, N-deacetylase, NAT2, and FAAH significantly impact the metabolism of paracetamol, influencing its hepato- and nephrotoxicity as well as its analgesic effects. Genetic variations in these enzymes can lead to varying benefit-risk ratios in paracetamol use.[11,12]

Pre-clinical and experimental evidence

Preclinical research has played a pivotal role in uncovering the analgesic properties of paracetamol. Studies employing various animal models have provided valuable insights into its effectiveness. These models often involve rodent species, such as mice and rats, and relevant pain assays, including the hot plate, tail flick, or formalin tests. These assays enable researchers to assess paracetamol's ability to relieve pain, determine the duration of its effects, and explore potential side effects. Furthermore, preclinical investigations have focused on establishing dose-response relationships, examining the connection between paracetamol dosage and its analgesic effects.[13]

Experimental studies have delved into the mechanisms through which paracetamol modulates inflammatory and nociceptive pathways. Research has concentrated on its selective action on COX enzymes, particularly COX-2, within the central nervous system. Additionally, investigations have explored how paracetamol interacts with neurotransmitters and receptors involved in pain perception and transmission. These include, among others, neural networks engaged in pain pathways, the role of paracetamol in inflammatory cascades, and its interactions with other analgesics. Ongoing laboratory research continues to produce emerging findings regarding paracetamol's broader impact, extending beyond pain relief to serve as an adjunctive analgesic with potential anti-inflammatory and immunomodulatory properties.[14,15]

Surgical procedures often trigger acute and intense pain, and while opioid-based analgesia is effective, it comes with various adverse effects, such as respiratory depression, sedation, and the risk of addiction. The need for adjunctive analgesics, like paracetamol, arises from the goal of optimizing pain management, reducing opioid-related complications, and improving the overall patient experience during and after surgery.[7] The peak analgesic activity of paracetamol typically occurs within 1-2 hours after administration, with duration of effect that varies depending on the formulation

and dosage. Generally, it provides pain relief for around 4-6 hours.[1]

In children, weight-based dosing is frequently used, accounting for an individual's body size and metabolism. The usual recommended dose ranges from 10 to 15 mg/kg of body weight for each dose. For instance, a patient weighing 7 kg would be dosed between 70 mg and 105 mg. However, in some cases, age may also be considered alongside weight, as children of the same weight may have varying medication needs based on their age. Dosing charts often account for both factors. For most adults, the maximum recommended daily dose to avoid the risk of overdose is typically around 4000 mg (4 gm).

Generally, IV paracetamol is considered safer for the liver than its oral counterpart when used appropriately and within recommended dosage guidelines. This is because IV administration can bypass the first-pass metabolism in the liver, reducing the liver's exposure to the drug's metabolites. However, certain factors, including underlying liver dysfunction, excessive alcohol consumption, and overdosage, may increase the likelihood of adverse effects.[16] To minimize potential complications, strategies should prioritize careful patient selection, appropriate dosing, and consideration of concurrent medications. Vigilance in monitoring is essential, including regular assessment of liver function, hemodynamic stability, and vital signs. This approach underscores the importance of early recognition of potential adverse events, such as signs of hepatotoxicity, allergic reactions, and overdose, enabling timely intervention and harm mitigation.[17,18] (Table 1)

Role of paracetamol in multimodal analgesia

Multimodal analgesia, a comprehensive approach that combines various medications and interventions with distinct mechanisms of

Table 1 Considerations in paracetamol administration

	Oral route	Intravenous route
Premedication	Not considered a first-line option because of lack of sedative or anxiolytic properties	
Peri-operative pain management	An adjunct to other analgesics to achieve better pain control with fewer side effects	A part of a multimodal analgesic regimen
Risk of hepatotoxicity	Metabolized in liver, primarily by CYP2E1, into NAPQI, which is normally detoxified by glutathione. In overdose, glutathione stores can become depleted, leading to accumulation of NAPQI, which is toxic to liver	Can bypass first-pass metabolism in liver and decreasing risk of hepatotoxicity compared to oral administration
Precautions	Individual responses vary, and some patients may be more susceptible to liver-related side effects	

action, aims to deliver more effective pain relief while minimizing side effects in peri-operative anesthesia care.[16] Paracetamol, when integrated with other analgesics like opioids, NSAIDs, and regional anesthesia techniques, assumes a crucial role. Its inclusion in multimodal analgesia offers several advantages, including the reduction of opioid consumption and the mitigation of opioid-related side effects. Furthermore, paracetamol stands out for its absence of adverse effects often associated with NSAIDs, like gastrointestinal bleeding. This approach not only ensures effective pain relief but also enhances patient satisfaction, improved post-operative outcomes, early ambulation, and heightened patient comfort.[19] (Table 2)

Implications and considerations

The adoption of enhanced recovery after surgery pathways and perioperative surgical home models reflects a concerted effort to systematically protocolize evidence-based medicine, ultimately aiming to enhance outcomes. The integration of paracetamol into these pathways stands as a potential breakthrough in optimizing care further, offering valuable insights into patient-specific responses to medications. Given the diverse pharmacologic agents employed at each stage, early integration of paracetamol into these pathways holds the promise of enabling precision medicine practices across all subsequent phases.[20,21] Examining the current evidence of paracetamol in relation to various drug classes relevant to surgical patients, such as opioids, nonopioids, antiemetics, anticoagulants, and β-blockers, becomes imperative.[22]

Genetic variability in these enzymes plays a pivotal role in determining drug toxicity and efficacy. Paracetamol information in the pre-surgery assessment emerges as a valuable tool for anesthesiologists, facilitating tailored and effective analgesic use for each patient. Different methods encompass diverse approaches, including intranasal, transdermal, and sustained-release formulations.[23,24] While the logical integration of paracetamol information holds promise, further studies are essential to comprehensively assess the effects of personalized dosing of anesthetics and

Table 2 Effectiveness of paracetamol compared to opioids and NSAIDs

	Paracetamol	Opioids	NSAIDs
Pain relief mechanism	Operates centrally within the brain to reduce pain perception	Binding to specific receptors in brain and spinal cord to block pain signals	Reducing inflammation and pain at site of injury
Strength of pain relief	Mild to moderate pain	Severe pain	Moderately severe pain
Side effects and safety	Generally safe, but excessive use can result in liver damage	Dependence and side effects, including sedation, respiratory depression, and constipation	Gastrointestinal symptoms and can affect kidney function

analgesics throughout the perioperative process, particularly in the context of various major surgeries.

Conclusion

This article explores the multifaceted role of paracetamol. It emphasizes the importance of taking into account individual patient profiles, pharmacogenomics, and potential risk factors. Paracetamol, as an adjunctive analgesic, offers a valuable tool for anesthesia practitioners in effectively managing peri-operative pain. Future directions underscore the dynamic nature of paracetamol's innovations, which include novel administration methods and formulations, promising to enhance its effectiveness further.

References

1. Freo U, Ruocco C, Valerio A, Scagnol I, Nisoli E. Paracetamol: a review of guideline recommendations. J Clin Med. 2021;10:3420.
2. Frauenknecht J, Kirkham KR, Jacot-Guillarmod A, Albrecht E. Analgesic impact of intra-operative opioids vs. opioid-free anaesthesia: a systematic review and meta-analysis. Anaesthesia. 2019;74:651-62.
3. Sharma CV, Mehta V. Paracetamol: mechanisms and updates. Cont Educ Anaesth Crit Care Pain. 2014;14:153-8.
4. Allegaert K, Olkkola KT, Owens KH, et al. Covariates of intravenous paracetamol pharmacokinetics in adults. BMC Anesthesiol. 2014;14:77.
5. Ohashi N, Kohno T. Analgesic effect of acetaminophen: a review of known and novel mechanisms of action. Front Pharmacol. 2020;11:580289.
6. Pickering G, Loriot MA, Libert F, Eschalier A, Beaune P, Dubray C. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther. 2006;79:371-8.
7. Ayoub SS. Paracetamol (acetaminophen): a familiar drug with an unexplained mechanism of action. Temperature. 2021;8:351-71.
8. Caparrotta TM, Antoine DJ, Dear JW. Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature. Eur J Clin Pharmacol. 2018;74:147-60.
9. García-Suástegui WA, Ramos-Chávez LA, Rubio-Osornio M, et al. The role of CYP2E1 in the drug metabolism or bioactivation in the brain. Oxid Med Cell Longev. 2017;2017:4680732.
10. Jarrar Y, Lee SJ. The functionality of UDP-glucuronosyltransferase genetic variants and their association with drug responses and human diseases. J Pers Med. 2021;11:554.
11. Zhao L, Pickering G. Paracetamol metabolism and related genetic differences. Drug Metab Rev. 2011;43:41-52.
12. Pickering G, Creveaux I, Macian N, Pereira B. Paracetamol and pain modulation by TRPV1, UGT2B15, SULT1A1 genotypes: a randomized clinical trial in healthy volunteers. Pain Med. 2020;21:661-9.
13. Hoshijima H, Hunt M, Nagasaka H, Yaksh T. Systematic review of systemic and neuraxial effects of acetaminophen in preclinical models of nociceptive processing. J Pain Res. 2021;14:3521-52.
14. Esh CJ, Chrismas BCR, Mauger AR, Taylor L. Pharmacological hypotheses: Is acetaminophen selective in its cyclooxygenase inhibition? Pharmacol Res Perspect. 2021;9:e00835.
15. Lee Y-S, Kim H, Brahim JS, Rowan J, Lee G, Dionne RA. Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain. 2007;129:279-86.
16. Freo U. Paracetamol for multimodal analgesia. Pain Manag. 2022;12:737-50.
17. Furyk J, Levas D, Close B, et al. Intravenous versus oral paracetamol for acute pain in adults in the emergency department setting: a prospective, double-blind, double-dummy, randomised con-

trolled trial. Emerg Med J. 2018;35:179-84.
18. Mallama M, Valencia A, Rijs K, Rietdijk W, Klimek M, Calvache JA. A systematic review and trial sequential analysis of intravenous vs. oral peri-operative paracetamol. Anaesthesia. 2021;76:270-6.
19. Zhou Y, Yuan P, Xing Q, Jin W, Shi C. Efficacy of postoperative analgesia with intravenous paracetamol and mannitol injection, combined with thoracic paravertebral nerve block in post video-assisted thoracoscopic surgery pain: a prospective, randomized, double-blind controlled trial. BMC Anesthesiol. 2024;24:14.
20. Chen Q, Chen E, Qian X. A narrative review on perioperative pain management strategies in enhanced recovery pathways-the past, present and future. J Clin Med. 2021;10:2568.
21. Simpson JC, Bao X, Agarwala A. Pain management in enhanced recovery after surgery (ERAS) protocols. Clin Colon Rectal Surg. 2019;32:121-8.
22. Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;2013:CD008040.
23. Ogawa K, Uchida M, Yamaki T, et al. Delivery of acetaminophen to the central nervous system and the pharmacological effect after intranasal administration with a mucoadhesive agent and absorption enhancer. Int J Pharm. 2021;594:120046.
24. Sintov AC, Krymberk I, Gavrilov V, Gorodischer R. Transdermal delivery of paracetamol for paediatric use: effects of vehicle formulations on the percutaneous penetration. J Pharm Pharmacol. 2003;55:911-9.